> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Biogen Swings To A $20.6 Million Quarterly Loss On A $283.8 Million RayThera Charge
- URL: https://www.bullished.co/biogen-swings-to-a-20-6-million-quarterly-loss-on-a-283-8-million-raythera-charge-08233730/
- Published: 2026-10-28T11:12:32.000Z
- Updated: 2026-10-28T11:12:32.000Z
- Description: The 10-Q also discloses a Swiss tax-law change and an $84.5 million fee to exit a Texas lease.
- Author: Matteo Parrino
- Tags: SEC Filings, BIIB, Industry: Healthcare

[Biogen](https://www.bullished.co/tag/biib/), the biopharmaceutical company behind multiple sclerosis and spinal muscular atrophy drugs, posted a third-quarter [net loss of $20.6 million](https://www.sec.gov/Archives/edgar/data/0000875045/000087504526000096/biib-20260930.htm?ref=bullished.co), or $0.14 a share, after booking $283.8 million of acquired research expense, mostly for its RayThera purchase. The quarterly report filed Wednesday also shows a Swiss tax-law change and a Texas lease buyout.

## The RayThera charge

Biogen completed the RayThera acquisition on August 6 with a $225.0 million upfront cash payment, expensed immediately because the deal was treated as an asset purchase. Milestones could add $275.0 million (development) and $500.0 million (regulatory).

Revenue still grew. Total revenue was $2,804.1 million against $2,534.7 million a year earlier, and the [earnings release](https://www.sec.gov/Archives/edgar/data/0000875045/000087504526000094/exhibit991-q32026pressrele.htm?ref=bullished.co) put adjusted diluted earnings at $2.62 a share. The company raised the low end of its full-year adjusted earnings guidance to a range of $12.20 to $13.00, from $12.00 to $13.00.

## A tax rate of negative 128.5%

Biogen booked $11.6 million of tax expense on a $9.0 million pretax loss, an effective rate of (128.5)%. The filing attributes the swing mainly to the non-deductible RayThera charge, partly offset by a decrease in valuation allowances on Swiss loss carryforwards "following a tax law change during the quarter." The Swiss effect carries no dollar figure.

The [prior quarter's 10-Q](https://www.sec.gov/Archives/edgar/data/0000875045/000087504526000075/biib-20260630.htm?ref=bullished.co) showed a 26.4% rate and no mention of the Swiss change.

## Paying $84.5 million to leave Plano

In September, Biogen exited its Plano, Texas, Reata building lease, paying about $84.5 million plus $16.3 million of rent over 12 months.

The company wrote off $143.6 million of lease liabilities and about $53.4 million of right-of-use assets, leaving a pre-tax loss of about $10.6 million. It had already booked a $52.9 million impairment on the lease in late 2025.

## Milestone debts move closer

Contingent consideration liabilities total $273.9 million, of which $152.4 million is now classed short-term. The expected timing of milestone achievement moved to 2027-2028, from 2028-2030 at year-end.

The restructuring reserve stood at $66.8 million at September 30, up from $35.9 million at June 30, as severance and Apellis integration costs continue. Biogen closed the Apellis acquisition in May, adding two eye and kidney drugs.

Biogen expects top-line data from its two late-stage litifilimab lupus trials in the first half of December 2026.

### Sources

- [10-Q Filing — Biogen (BIIB)](https://www.sec.gov/Archives/edgar/data/0000875045/000087504526000096/biib-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Biogen (BIIB), Q2 FY2026 filed 2026-07-29 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0000875045/000087504526000075/biib-20260630.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, exhibit991-q32026pressrele.htm) — Biogen, filed 2026-10-28](https://www.sec.gov/Archives/edgar/data/0000875045/000087504526000094/exhibit991-q32026pressrele.htm?ref=bullished.co) — SEC EDGAR
- [Biogen Has 'Returned To Growth,' Says CEO — What To Know About Its Report | Investor's Business Daily](https://www.investors.com/news/technology/biogen-stock-biogen-earnings-q3-2026/?ref=bullished.co) — investors.com
- [Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?](https://finance.yahoo.com/healthcare/articles/biogen-q3-preview-growth-products-123800609.html?ref=bullished.co) — Yahoo Finance
- [Biogen (BIIB) Nears Earnings As Investors Ask If The Stock Is Already Fully Valued](https://finance.yahoo.com/markets/stocks/articles/biogen-biib-nears-earnings-investors-140907655.html?ref=bullished.co) — Yahoo Finance
- [Biogen Crushes Earnings Estimates. As Old Blockbusters Fade, New Bets Pick Up the Slack.](https://www.barrons.com/articles/biogen-earnings-stock-price-2ccad9ac?mod=RTA&ref=bullished.co) — Barron's
- [Biogen (BIIB) Stock May Be 45% Undervalued Despite Fresh Kidney Data](https://uk.finance.yahoo.com/news/biogen-biib-stock-may-45-131931134.html?ref=bullished.co) — Yahoo Finance

### More on Biogen

- [Biogen Posts A $0.14 Per-Share Loss On RayThera Deal Charge As Growth Drugs Climb 49%](https://www.bullished.co/biogen-posts-a-0-14-per-share-loss-on-raythera-deal-charge-as-growth-drugs-climb-49-c62de7e2/)

[All Biogen (BIIB) coverage →](https://www.bullished.co/tag/biib/)